>
Switch to:

Biomarin Pharmaceutical Shiller PE Ratio

: (As of Today)
View and export this data going back to 1999. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Shiller PE Ratio falls into.



Biomarin Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biomarin Pharmaceutical's E10 for the quarter that ended in Sep. 2021 is calculated as:

For example, Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Sep. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2021 (Change)*Current CPI (Sep. 2021)
=-0.2/115.7343*115.7343
=-0.200

Current CPI (Sep. 2021) = 115.7343.

Biomarin Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201112 -0.240 95.213 -0.292
201203 -0.210 96.783 -0.251
201206 -0.270 96.819 -0.323
201209 -0.040 97.633 -0.047
201212 -0.430 96.871 -0.514
201303 -0.310 98.209 -0.365
201306 -0.160 98.518 -0.188
201309 -0.380 98.790 -0.445
201312 -0.440 98.326 -0.518
201403 -0.270 99.695 -0.313
201406 -0.230 100.560 -0.265
201409 0.050 100.428 0.058
201412 -0.470 99.070 -0.549
201503 -0.430 99.621 -0.500
201506 -0.510 100.684 -0.586
201509 -0.600 100.392 -0.692
201512 0.390 99.792 0.452
201603 -0.510 100.470 -0.587
201606 -2.580 101.688 -2.936
201609 -0.220 101.861 -0.250
201612 -0.530 101.863 -0.602
201703 -0.090 102.862 -0.101
201706 -0.210 103.349 -0.235
201709 -0.070 104.136 -0.078
201712 -0.300 104.011 -0.334
201803 -0.260 105.290 -0.286
201806 -0.090 106.317 -0.098
201809 -7.000 106.507 -7.606
201812 -0.030 105.998 -0.033
201903 -0.320 107.251 -0.345
201906 -0.210 108.070 -0.225
201909 0.300 108.329 0.321
201912 0.080 108.420 0.085
202003 0.440 108.902 0.468
202006 -0.160 108.767 -0.170
202009 4.010 109.815 4.226
202012 0.120 109.897 0.126
202103 0.090 111.754 0.093
202106 0.070 114.631 0.071
202109 -0.200 115.734 -0.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (NAS:BMRN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biomarin Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)